Estimation of PfRh5-based vaccine efficacy in asymptomatic Plasmodium falciparum patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening

Estimation of PfRh5-based vaccine efficacy in asymptomatic Plasmodium falciparum patients from high-endemic areas of Tanzania using genetic and antigenicity variation screening

BackgroundPlasmodium falciparum is the most lethal malaria parasite. Recent phase 1b vaccine trials using P. falciparum reticulocyte binding protein homolog 5 (PfRh5) demonstrated safety and promising efficacy in preventing merozoite invasion. PfRh5 has emerged as a strong vaccine candidate due to i...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Hojong Jun, Ernest Mazigo, Wang-Jong Lee, Johnsy Mary Louis, Jadidan Hada Syahada, Fadhila Fitriana, Jin Heo, Yeonkyung Kim, Boeun Kwon, Fauzi Muh, Feng Lu, Md Atique Ahmed, Se Jin Lee, Sunghun Na, Wanjoo Chun, Won Sun Park, Min Hong, Joon-Hee Han, Tae-Hyung Kwon, Soo-Ung Lee, Eun-Teak Han, Jim Todd, Alphaxard Manjurano, Winifrida Kidima, Jin-Hee Han
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Frontiers Media S.A. 2024-11-01
Sarja:Frontiers in Immunology
Aiheet:
malaria
Plasmodium falciparum
asymptomatic
Tanzania
PfRh5
genetic variation
Linkit:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495513/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1495513/full

Samankaltaisia teoksia